Compugen Appoints Mr. Ari Krashin as Chief Financial Officer
August 25 2014 - 7:09AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN), a leading drug discovery company
focused on therapeutic proteins and monoclonal antibodies in the
fields of immunology and oncology, today announced the appointment
of Mr. Ari Krashin as Chief Financial Officer, effective as of
September 9, 2014. Mr. Krashin will report to Dr. Anat Cohen Dayag,
Compugen’s President and Chief Executive Officer, and will have
direct responsibility for all financial functions of the company,
including investor relations, and in addition will oversee the
legal function.
Dr. Cohen-Dayag stated, “With over 15 years of experience in all
aspects of finance, investor relations, M&A and business
development, Mr. Krashin brings substantial global finance
expertise to Compugen. We very much look forward to Mr. Krashin's
contribution to our senior management team, particularly during
this period of anticipated rapid growth and expansion for our
company.”
Mr. Krashin added, “I am enthusiastic about
joining Compugen and its dedicated management team at this
pivotal time in the Company's development, and hope my experience
will contribute to its future success.”
Mr. Krashin previously served as Chief Financial Officer of
Gilat Satellite Networks (Nasdaq: GILT) where he was responsible
for the company's global finance and related operations, including
M&A, business development, investor relations and
administration. Prior to his position as CFO of Gilat, Mr. Krashin
held a variety of senior financial positions in Gilat. Mr. Krashin
also served as CFO of Spacenet, a US subsidiary of Gilat. In
addition, he recently served as CFO of AnyClip Media. Mr. Krashin
is a certified public accountant and began his professional career
with Kesselman and Kesselman, PWC, Israel.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of product
candidates, which are then advanced in its Pipeline Program. The
Company's business model includes collaborations covering the
further development and commercialization of product candidates at
various stages from its Pipeline Program and various forms of
research and discovery agreements, in both cases providing Compugen
with potential milestone payments and royalties on product sales or
other forms of revenue sharing. Compugen’s wholly-owned U.S.
subsidiary located in South San Francisco is developing monoclonal
antibody therapeutic candidates against its drug targets. For
additional information, please visit Compugen's corporate website
at http://www.cgen.com/.
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include words such as “may,” “expects,”
“anticipates,” “potential,” “believes,” and “intends,” and describe
opinions about future events. These forward-looking statements
involve known and unknown risks and uncertainties that may cause
the actual results, performance or achievements of Compugen to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Some of these risks and other factors are discussed in
the "Risk Factors" section of Compugen’s Annual Report on Form 20-F
for the year ended December 31, 2013 as filed with the Securities
and Exchange Commission. In addition, any forward-looking
statements represent Compugen’s views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Compugen does not assume any obligation to
update any forward-looking statements unless required by law.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@netvision.net.il
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From May 2023 to May 2024